Trial · NCT07884188
Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer
NCT07884188, Phase 2, Recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer. Trials, record NCT07884188. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884188
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer
- NCT number
- NCT07884188
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 31 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Becotatug Vedotin (MRG003), Pucotenlimab
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | From the first dose of study treatment through the end of tumor response assessment, up to 24 months. | Percentage of participants whose best overall response is complete response (CR) or partial response (PR), assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) |
| Secondary | Disease Control Rate (DCR) | From the first dose of study treatment through the end of tumor response assessment, up to 24 months. | Percentage of participants whose best overall response is confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD), assessed according to RECIST version 1.1. |
| Secondary | Duration of Response (DOR) | From the first dose of study treatment through the end of tumor response assessment, up to 24 months. | Time from the first documentation of complete response (CR) or partial response (PR) to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. DOR will be assessed in participants with a confirmed objective response. Participants without progression or death will be censored at their last tumor assessment. |
| Secondary | Progression-Free Survival (PFS) | From the first dose of study treatment to disease progression or death, assessed up to 24 months. | Time from the first dose of study treatment to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Participants without progression or death will be censored at their last tumor assessment. |
| Secondary | Overall Survival (OS) | From the first dose of study treatment to death from any cause, assessed up to 24 months. | Time from the first dose of study treatment to death from any cause. Participants without a reported death at the time of analysis will be censored at the date they were last known to be alive. |
| Secondary | Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) | From the first dose of study treatment through 30 days after the last dose. | Percentage of participants experiencing treatment-emergent adverse events. Events will be summarized by type and severity, with severity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. |
| Secondary | Incidence and Severity of Treatment-Related Adverse Events (TRAEs) | From the first dose of study treatment through 30 days after the last dose. | Percentage of participants experiencing adverse events considered related to either study drug by the investigator. Events will be graded according to NCI-CTCAE version 5.0. The percentage of participants experiencing Grade 3 or higher treatment-related adverse events will also be reported. |
| Secondary | Incidence of Serious Adverse Events (SAEs) | From the first dose of study treatment through 30 days after the last dose, with subsequent collection of study-treatment-related SAEs as specified in the protocol. | Percentage of participants experiencing serious adverse events. Events will be summarized by type, severity, and relationship to study treatment. Seriousness and severity will be assessed separately, with severity graded according to NCI-CTCAE version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884188
GET https://conductscience.org/api/trials/v1/NCT07884188/registered